Sartorius Stedim gets fresh JPMorgan Buy, shares react to upbeat stance
22.06.2026 - 16:58:32 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 16:56.
Sartorius Stedim (FR0013154002) draws attention on Euronext Paris after JPMorgan reiterated a Buy rating and a 260 euro target price for the biotech supplier in a note published on 2026-06-22, as reported by MarketScreener.MarketScreener summary of the JPMorgan rating
What JPMorgan highlights
According to MarketScreener, JPMorgan analyst Richard Vosser keeps Sartorius Stedim Biotech at Buy with a target price of 260 euros, leaving the objective unchanged in the latest 2026-06-22 research update.MarketScreener summary of the JPMorgan rating The report notes that the stock remains down around 22 percent year to date despite the positive stance, based on MarketScreener performance data for 2026.MarketScreener share overview with YTD performance
MarketScreener quotes a last price around 164.20 euros for Sartorius Stedim Biotech in real-time other markets on the morning of 2026-06-22, corresponding to an intraday gain of about 0.55 percent versus the previous close.MarketScreener summary of the JPMorgan rating The shares show a one-year decline of roughly 22 percent, illustrating ongoing pressure in the life-science tools segment.
Analyst consensus and peer context
Analyst data compiled by MarketScreener indicate that Sartorius Stedim Biotech is followed by several major banks, with a mix of Buy and Hold recommendations and an average target price in the mid-200 euro range, implying upside versus current trading levels.MarketScreener consensus overview In the broader European healthcare equipment space, peers such as Sartorius Vz, Danaher and Thermo Fisher also experienced valuation resets after the pandemic-driven demand peak.
Deutsche Bank recently reiterated a Buy rating on the separate Sartorius Vz listing in Germany with a 284 euro target price, underscoring that parts of the group remain on the radar of DAX-oriented investors.MarketScreener note on Deutsche Bank rating for Sartorius Vz That German-listed stock trades in the DAXsector Pharma & Healthcare Performance-Index, giving Sartorius additional visibility on Xetra.
All news and analysis on the Sartorius Stedim Biotech shares
Follow further ratings, earnings dates and price data on Sartorius Stedim Biotech in the dedicated topic area and on the company’s investor relations pages.
The business behind the rating
Sartorius Stedim Biotech focuses on single-use and filtration technologies for biopharmaceutical production, supplying bioreactors, filters and fluid management systems used in upstream and downstream processing.Company description on the Sartorius website The company’s portfolio targets biopharma customers developing monoclonal antibodies, vaccines and advanced therapies.
Where the shares trade today
The Sartorius Stedim shares (FR0013154002) most recently traded on Euronext Paris at 164.20 euros in the morning session on 2026-06-22, according to MarketScreener price data.MarketScreener summary of the JPMorgan rating
Key data on the Sartorius Stedim Biotech shares
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- WKN: A2AJ68
- Ticker: DIM
- Trading venue: Euronext Paris
- Price (as of 2026-06-22, 10:30): 164.20 EUR
- Market cap: approximately 18.0 billion EUR (as of 2026-06-22)
- Sector / industry: Healthcare equipment and supplies / bioprocessing
- Index membership: SBF 120
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument.
